DrugMR is a Nextflow pipeline that runs cis-Mendelian randomisation, colocalisation, SMR-HEIDI with bulk and/or single-cell QTLs, three-trait colocalisation and a phenome-wide screen for adverse effects and repurposing, applied to schizophrenia with brain pQTLs.
Abstract
Motivation Genetically supported drug targets are an estimated 2.6 times more likely to succeed clinically, yet a disease association alone does not show which protein to target, in which direction, or what other effects may follow. This currently requires chaining separate tools. Results drugMR is a Nextflow pipeline that, from GWAS and pQTL summary statistics, runs cis-Mendelian randomisation, colocalisation, SMR-HEIDI with bulk and/or single-cell QTLs, three-trait colocalisation and a phenome-wide screen for adverse effects and repurposing. Datasets are added through a manifest, every step runs in containers on a laptop, cluster or cloud, and results are explored in a dashboard. Applied to schizophrenia with brain pQTLs, drugMR tested 2,019 proteins in 4 h 19 min and prioritised 58 proteogenomic targets, 22 with multi-omic support; 4 had potential adverse effects. Availability and implementation drugMR: https://github.com/guillermocomesa_nacimadevila/drugMR; documentation: https://guillermocomesanacimadevila.github.io/drugMR/. Demo data: https://doi.org/10.5281/zenodo.22917384.
Genome-scale association studies and functional screens routinely implicate hundreds of candidate genes per disease, yet only a few will be clinically validated as drug targets. Choosing which to pursue is a central drug-discovery decision that depends on interpreting each candidate in its biological context. Curated p...
Polina Rusina, D. Ochoa, Franck Rapaport et al.· Drug Discovery Today· 0 citations
Despite prolific genomic data from individuals with Alzheimer's disease (AD), translation into treatments has lagged. Here we applied Mendelian randomization to multiple AD genome-wide association studies and functional multiomics datasets to nominate druggable targets, identifying 19 targets for individuals of Europea...
The All of Us (AoU) Research Program multi-omics cohort was developed to expand discovery of the molecular mechanisms underlying health and disease. Here, we report on the AoU multi-omics cohort comprising proteomic (N = 10,043) and transcriptomic (N = 9,043) sequencing data generated from ancestrally diverse AoU parti...
E. Padhi, E. Kiernan, Jonathan Nguyen et al.· medRxiv· 0 citations
The 32 proteins with nominal MR associations represent candidates for follow-up investigation and should be interpreted as exploratory because a verified proteome-wide FDR correction could not be established.
Hong-Yuan Zhang, Jing Zou, Yan-Hong Zhao et al.· Computational biology and ch...· 0 citations
Background More than 90% of rare diseases lack an approved therapy, partly reflecting economic barriers in developing treatments for small patient populations. A common bottleneck is costly and resource-intensive hit-to-lead prioritization. Congenital contractures of the limbs and face, hypotonia, and developmental del...
N. Thongsepee, Jeremy A. Tanner, Srikanth R. Polusani et al.· bioRxiv· 0 citations
The groundwork for an AI co-scientist framework for the sequential analysis of multi-batch spatial transcriptomics data that integrates interpretable mathematical models, including optimal transport, tensor factorizations, and topological data analysis, with LLM-powered agentic interpretation is presented.
Sean Cottrell, Guo-Wei Wei· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.